| abstract |
Use of a compound of formula (I): or of one of its salts, solvates, esters or amides, for the manufacture of a medicament for treating disorders mediated by GlyT1, in which: R1 and R2 are independently selected from an atom of hydrogen, a C1-C6 alkyl group and a C3-C6 cycloalkyl group, with the proviso that R1 and R2 do not both represent a hydrogen atom, or R1 and R2 together with the nitrogen atom to which they are attached bind to form a saturated ring of 5, 6 or 7 members, in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O, and S, said saturated ring being optionally substituted by one or more Independently selected groups of a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C3-C6-C1-C4 alkyl cycloalkyl group, an aryl group and a C1-C4 aryl-alkyl group, and being further said optionally saturated ring p based on a C1-C3 alkylene group, and said saturated ring being optionally fused to a C5-C7 alicyclic group or a 5- or 6-membered aromatic or heteroaromatic ring optionally substituted by one or more groups independently selected from an alkyl group C1-C6 and a C3-C6 cycloalkyl group; R3 is where Y is a C1-C2 alkylene group, a C2 alkenylene group or a C2 alkynylene group, and n is 0 or 1, and Z is a 5- to 8-membered monocyclic or 6-bicyclic aromatic ring system to 10 members in which one or more of the carbon atoms is optionally replaced by a heteroatom independently selected from N, O and S, and said ring system is optionally substituted by one or more groups independently selected from -hal, R10, -CF3, -C1-6-sulfonyl alkyl, -OR11, -COOR12, -CN, -NO2, -NR13R14, -C (O) NR15R16, -NR17C (O) R18, -C (O) R19, -C (NR20) NR21R22, -C (NOR23) R28, where hal is F, Cl, Br ol, R10 is a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C3-C6-alkyl cycloalkyl group of C1-C4, an aryl group, an aryloxy group or an aryl-C1-C4 alkyl group, optionally substituted by one or more groups independently selected from hal, C1-C6 alkyl, -OR11, -COOR12 -CN, - NO2 and -NR13R14, R11, R 12, R13, R14, R15, R16, R17, R18, R20, R21, R22, R23 and R28 are independently selected from a hydrogen atom and a C1-C6 alkyl group; R4 and R19 are independently selected from a hydrogen atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, an aryl group or an aryl-C1-C4 alkyl group, optionally substituted by one or more groups independently selected from hal, C1-C6 alkyl, -OR24, -COOR25, CN, -NO2 and -NR26R27; R6, R7, R8 and R9 are independently selected from a hydrogen atom, a C1-C6 alkyl group or a C1-C4 aryl-alkyl group, or R6 and R7 together form a C3-C6 cycloalkyl group, or R8 and R9 together form a C3-C6 cycloalkyl group; wherein the C1-C6 alkyl group, the aryl-C1-C4 alkyl group, the C3-C6 cycloalkyl group formed by R6 and R7, and the C3-C6 cycloalkyl group formed by R8 and R9 are optionally substituted by one or more groups independently selected from hal, a C1-C6 alkyl group, -OR24, -COOR25, -CN, -NO2 and -NR26R27, wherein R24, R25, R26 and R27 are independently selected from a hydrogen atom and a C1-C6 alkyl group; and R5 is independently selected from a hydrogen atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, an aryl group and an aryl-C1-C4 alkyl group, optionally substituted by one or more independently selected groups of hal, C1-C6 alkyl, -OR24, -COOR25, -CN, -NO2 and -NR26R27, wherein R24, R25, R26 and R27 are as defined hereinbefore, and where the expression "a aryl group "refers to a 5- to 7-membered aromatic or heteroaromatic ring system in which the heteroatomic ring contains at least one heteroatom selected from N, O and S. |